This distinction allows researchers to distinguish between factors that may help halt or slow the development or progression of AD pathological processes (e.g., Aβ and tau) (“resistance”) versus factors that delay or slow processes downstream of Aβ and tau burden and ultimately reduce or delay the clinical expression of AD (“resilience”).15 The gene discussed is MAPT; the disease is Alzheimer disease.